Why Farbe Firma is the Top Manufacturer of Vancomycin for Injection
- Maulik Sudani
- 4 hours ago
- 7 min read
Last Updated: June 1, 2026
TL;DR: Vancomycin for Injection — a sterile lyophilised powder of the glycopeptide antibiotic vancomycin hydrochloride, supplied most commonly as 500 mg and 1 g vials for reconstitution and dilution before slow intravenous infusion — is a cornerstone agent against serious Gram-positive infection, including methicillin-resistant Staphylococcus aureus (MRSA), coagulase-negative staphylococci, enterococci and resistant streptococci: bacteraemia, infective endocarditis, bone and joint infection, complicated skin and soft-tissue infection, hospital-acquired pneumonia, central-nervous-system infection and febrile neutropenia. Because vancomycin has a narrow therapeutic window that demands therapeutic drug monitoring, and because too-rapid infusion provokes the histamine-mediated vancomycin infusion reaction, its safe use depends on accurate potency, a clean fast-reconstituting cake and low endotoxin. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Vancomycin for Injection at our Gujarat, India facility and supplies it to hospital pharmacy, infectious-disease and critical-care services, tenders, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Glycopeptide antibiotic — Vancomycin for Injection is a cornerstone agent for serious Gram-positive infection including MRSA bacteraemia, infective endocarditis, bone and joint infection, complicated skin and soft-tissue infection, hospital-acquired pneumonia and febrile neutropenia, acting by inhibiting bacterial cell-wall peptidoglycan synthesis and requiring therapeutic drug monitoring for safe, effective dosing.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, qualified lyophilisation (freeze-drying) lines for vials, dedicated control of potency, residual moisture and endotoxin for a narrow-therapeutic-window glycopeptide whose assay must be held batch to batch, with validated lyophilisation cycles, shelf mapping and container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, ICH Q1B photostability data, drug master files and CEP-style documentation for registrations including ministry-of-health, antimicrobial-stewardship-programme and hospital tenders.
End-to-end CDMO services: Contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tender-ready vial packaging and logistics coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Vancomycin for Injection Demands a Premium Manufacturer
Vancomycin for Injection occupies one of the most important places on the antimicrobial shelf. It is the glycopeptide that infectious-disease physicians and intensivists turn to when a serious infection is caused by a resistant Gram-positive organism — methicillin-resistant Staphylococcus aureus, coagulase-negative staphylococci, ampicillin-resistant enterococci or penicillin-resistant streptococci — and a beta-lactam will not work. It is used to treat bacteraemia and infective endocarditis, bone and joint infection such as osteomyelitis and prosthetic-joint infection, complicated skin and soft-tissue infection, hospital- and ventilator-associated pneumonia, central-nervous-system infection and Gram-positive sepsis in febrile neutropenic patients. It is given by slow intravenous infusion, and in every one of these settings the patient is seriously ill and the dose must be both potent and reliably delivered.
That clinical reality places real demands on the manufacturer. Vancomycin is a large, complex glycopeptide molecule produced by fermentation, supplied as vancomycin hydrochloride, and its activity depends on a controlled impurity and degradation profile. It has a narrow therapeutic window: too little risks treatment failure and resistance, while excessive exposure is associated with nephrotoxicity, so dosing is guided by therapeutic drug monitoring against a target AUC or trough. It is supplied as a lyophilised powder for reconstitution because the concentrated solution is not stable for long-term storage, and the freeze-dried cake must dissolve quickly and completely so that ward staff can prepare an accurate infusion. Too-rapid infusion provokes the histamine-mediated vancomycin infusion reaction, so the product must reconstitute cleanly and carry low endotoxin. Choosing a Vancomycin for Injection manufacturer that treats potency, residual moisture, endotoxin and container-closure integrity as core engineering disciplines is what protects the patient with a serious Gram-positive infection at the bedside.
What Sets a World-Class Vancomycin for Injection Manufacturer Apart
A world-class manufacturer of Vancomycin for Injection invests in three areas that weaker suppliers underfund: exact potency assay and a tightly controlled impurity profile by HPLC for a fermentation-derived glycopeptide where activity and tolerability depend on composition, a validated lyophilisation cycle that yields an elegant, fast-reconstituting cake with low residual moisture, and tender-ready dossier support for a product procured almost entirely through hospital, antimicrobial-stewardship and ministry-of-health channels. It starts with the active — pharmacopoeial-grade vancomycin hydrochloride sourced from qualified, audited fermentation-API makers, with full impurity profiling, microbiological potency assay, water-content control and certificates of analysis verified by the receiving laboratory before the material enters production.
Formulation, filling and lyophilisation then have to preserve both potency and the dose. The bulk solution is compounded at controlled pH, sterile-filtered through 0.22 µm membrane, filled aseptically into clear-glass vials under ISO Class 5 air and then freeze-dried on validated shelves. The cycle parameters — freezing rate, sublimation pressure, secondary-drying time and final residual moisture — are locked in the master batch record, because residual moisture governs both the long shelf life and the speed of reconstitution. The vial is stoppered with a lyophilisation stopper under controlled headspace; in-process and release testing confirm potency by HPLC and microbiological assay, the impurity profile, reconstitution time, pH and the clarity of the reconstituted solution. Endotoxin is held well within limits so the diluted infusion is safe for slow intravenous delivery.
Quality Systems Behind Every Vancomycin for Injection
Every Farbe Firma Vancomycin for Injection batch is released only after a full stack of quality checks: HPLC and microbiological potency assay against USP, BP, IP or EP reference standards, control of vancomycin B content, related substances and degradation products by HPLC, residual moisture by Karl Fischer titration, reconstitution time and appearance of the reconstituted solution, pH and osmolarity, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, container-closure integrity and fill-weight verification for the 500 mg and 1 g vial formats. Certificates of analysis are issued with full traceability back to the API lot, the primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, calibrated sterilisation and depyrogenation equipment, validated lyophilisation cycles with shelf and load mapping, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because vancomycin is a narrow-therapeutic-window glycopeptide whose potency and residual moisture drive both efficacy and shelf life, we treat the HPLC assay and Karl Fischer moisture result as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under both long-term (30 °C / 65 % RH) and accelerated (40 °C / 75 % RH) ICH Q1A conditions, with ICH Q1B photostability challenge.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Vancomycin for Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables across anti-infective, critical-care, anaesthesia, oncology-supportive and supportive-care categories. For Vancomycin for Injection specifically, we supply 500 mg and 1 g lyophilised vials under WHO-GMP conditions, with country-specific formats and pack configurations available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier — including the lyophilisation-cycle validation and potency-and-impurity data package — ready to hand for registration.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, potency and related-substances method-validation data, translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics. When a buyer needs Vancomycin for Injection at tender scale our regulatory, manufacturing and logistics teams move as one: dossier, lyophilisation-validation report, artwork, freeze-dryer slot and shipment plan delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor and into the lyophilisation suite; our quality unit answers technical queries with primary data, not slogans; and our reviewer team — practising pharmacists and R&D scientists — can talk through API potency sourcing, lyophilisation-cycle development, residual-moisture control, reconstitution behaviour, endotoxin management, container-closure and stability choices in real detail. For a glycopeptide given to seriously ill patients with resistant Gram-positive infection, where potency and reliable reconstitution directly govern outcomes, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Vancomycin for Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Vancomycin for Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, qualified lyophilisation suites, qualified vial filling lines, qualified water-for-injection systems, validated freeze-drying cycles and continuous environmental monitoring.
Which strengths and pack sizes of Vancomycin for Injection do you supply?
Our standard presentations are 500 mg and 1 g vancomycin (as vancomycin hydrochloride) as a lyophilised powder for reconstitution in clear-glass vials. Custom fill weights, bulk-pharmacy presentations and country-specific artwork are available under contract manufacturing agreements.
Can Farbe Firma support country-specific registrations for Vancomycin for Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, potency and related-substances method-validation data, lyophilisation-cycle validation reports, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. We support registrations in 30+ countries across Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
How does Farbe Firma assure the quality and safety of Vancomycin for Injection?
We control vancomycin potency and related substances by HPLC and microbiological assay against pharmacopoeial standards, verify residual moisture by Karl Fischer titration, qualify reconstitution time and solution clarity, hold endotoxin well within limits by LAL, lock the lyophilisation cycle to a validated profile, run particulate and sterility testing, verify container-closure integrity on every batch, and qualify each batch against ICH Q1A and ICH Q1B protocols.
What is the minimum order quantity for Vancomycin for Injection contract manufacturing?
MOQs vary by vial strength, freeze-dryer load size, label complexity and dossier requirements. For the 500 mg and 1 g presentations we accommodate hospital-scale and full national-tender-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments